Skip to main content
Top

15-04-2024 | Epstein-Barr Virus | Case Report

Spontaneous regression of multiple solitary plasmacytoma harboring Epstein–Barr virus: a case report and literature review

Authors: Wataru Kitamura, Hiroki Kobayashi, Minori Noda, Akiko Iseki, Yumi Sato, Yoshinobu Maeda, Shoichi Kuyama

Published in: International Journal of Hematology

Login to get access

Abstract

We report a rare case of spontaneous regression (SR) in an elderly untreated patient with multiple solitary plasmacytoma (MSP). Diagnosis of MSP was confirmed through surgical resection of the left nasal cavity mass and subsequent biopsy of the right humerus. The patient was considered ineligible for chemotherapy due to poor performance status. At 3-month post-diagnosis, the patient’s condition worsened with deteriorating bone lesions and emergence of a new serum monoclonal protein. However, these clinical findings completely disappeared at 6 months, and positron emission tomography–computed tomography at 1 year confirmed complete metabolic remission. Notably, peripheral blood lymphocyte counts were inversely correlated with tumor progression and remission. Pathological re-evaluation of the initial biopsy specimens revealed programmed cell death protein 1 (PD-1) expression in tumor-infiltrating CD8+ T cells. In addition, tumor cells were infected with Epstein–Barr virus (EBV) but were negative for programmed cell death ligand 1 (PD-L1) expression, which is the most potent immune escape mechanism in tumor cells. While the mechanism underlying SR remains unclear, our findings suggest that host immune response as well as EBV infection may contribute to SR. Further studies are needed to elucidate the clinicopathologic mechanisms of tumor regression in plasma cell neoplasms.
Literature
1.
go back to reference Group IMW. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749–57.CrossRef Group IMW. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749–57.CrossRef
2.
go back to reference Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–48.CrossRefPubMed Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–48.CrossRefPubMed
3.
go back to reference Caers J, Paiva B, Zamagni E, Leleu X, Blade J, Kristinsson SY, et al. Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. J Hematol Oncol. 2018;11:10.CrossRefPubMedPubMedCentral Caers J, Paiva B, Zamagni E, Leleu X, Blade J, Kristinsson SY, et al. Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. J Hematol Oncol. 2018;11:10.CrossRefPubMedPubMedCentral
4.
go back to reference Tsang RW, Campbell BA, Goda JS, Kelsey CR, Kirova YM, Parikh RR, et al. Radiation therapy for solitary plasmacytoma and multiple myeloma: guidelines from the international lymphoma radiation oncology group. Int J Radiat Oncol Biol Phys. 2018;101:794–808.CrossRefPubMed Tsang RW, Campbell BA, Goda JS, Kelsey CR, Kirova YM, Parikh RR, et al. Radiation therapy for solitary plasmacytoma and multiple myeloma: guidelines from the international lymphoma radiation oncology group. Int J Radiat Oncol Biol Phys. 2018;101:794–808.CrossRefPubMed
5.
go back to reference Zhang Y, Qi J, Qiu L. Multiple solitary plasmacytoma: characteristics, response to therapy, survival in nine patients from a single institute. Blood. 2013;122:5383.CrossRef Zhang Y, Qi J, Qiu L. Multiple solitary plasmacytoma: characteristics, response to therapy, survival in nine patients from a single institute. Blood. 2013;122:5383.CrossRef
6.
go back to reference Yang B, Wang J, Cai LL, Zhu HL, Yu RL, Chi XH, et al. Treatment of multiple solitary plasmacytomas with cytokine-induced killer cells. Cytotherapy. 2014;16:278–84.CrossRefPubMed Yang B, Wang J, Cai LL, Zhu HL, Yu RL, Chi XH, et al. Treatment of multiple solitary plasmacytomas with cytokine-induced killer cells. Cytotherapy. 2014;16:278–84.CrossRefPubMed
7.
go back to reference Cafferata MA, Chiaramondia M, Monetti F, Ardizzoni A. Complete spontaneous remission of non-small-cell lung cancer: a case report. Lung Cancer. 2004;45:263–6.CrossRefPubMed Cafferata MA, Chiaramondia M, Monetti F, Ardizzoni A. Complete spontaneous remission of non-small-cell lung cancer: a case report. Lung Cancer. 2004;45:263–6.CrossRefPubMed
8.
go back to reference Wiernik PH. Spontaneous regression of hematologic cancers. Natl Cancer Inst Monogr. 1976;44:35–8.PubMed Wiernik PH. Spontaneous regression of hematologic cancers. Natl Cancer Inst Monogr. 1976;44:35–8.PubMed
9.
go back to reference Gattiker HH, Wiltshaw E, Galton DA. Spontaneous regression in non-Hodgkin’s lymphoma clinical and pathogenetic considerations. Cancer. 1980;45:2627–32.CrossRefPubMed Gattiker HH, Wiltshaw E, Galton DA. Spontaneous regression in non-Hodgkin’s lymphoma clinical and pathogenetic considerations. Cancer. 1980;45:2627–32.CrossRefPubMed
10.
go back to reference Drobyski WR, Qazi R. Spontaneous regression in non-Hodgkin’s lymphoma clinical and pathogenetic considerations. Am J Hematol. 1989;31:138–41.CrossRefPubMed Drobyski WR, Qazi R. Spontaneous regression in non-Hodgkin’s lymphoma clinical and pathogenetic considerations. Am J Hematol. 1989;31:138–41.CrossRefPubMed
12.
go back to reference Arunabh, Dutta Gupta S, Bal S, Sarda A, Vijayraghavan M, Shukla N, et al. Spontaneous regression of extramedullary plasmacytoma -a case report. Jpn J Surg. 1988;18:455–9.CrossRefPubMed Arunabh, Dutta Gupta S, Bal S, Sarda A, Vijayraghavan M, Shukla N, et al. Spontaneous regression of extramedullary plasmacytoma -a case report. Jpn J Surg. 1988;18:455–9.CrossRefPubMed
13.
go back to reference Meziane M, Boulaadas M, Essakalli L, Kzadri M, Harmouch A. Solitary plasmocytoma: ghost tumour? Int J Oral Maxillofac Surg. 2012;41:17–9.CrossRefPubMed Meziane M, Boulaadas M, Essakalli L, Kzadri M, Harmouch A. Solitary plasmocytoma: ghost tumour? Int J Oral Maxillofac Surg. 2012;41:17–9.CrossRefPubMed
14.
go back to reference Oken M, Creech R, Tormey D, Horton J, Davis T, McFadden E, et al. Toxicity and response criteria of the Eastern cooperative oncology group. Am J Clin Onco. 1982;5:649–55.CrossRef Oken M, Creech R, Tormey D, Horton J, Davis T, McFadden E, et al. Toxicity and response criteria of the Eastern cooperative oncology group. Am J Clin Onco. 1982;5:649–55.CrossRef
15.
go back to reference Abe R, Ogawa K, Maruyama Y, Nakamura N, Abe M. Spontaneous regression of diffuse large b-cell lymphoma harbouring epstein-barr virus a case report and review of the literature. J Clin Exp Hematop. 2007;47:23–6.CrossRefPubMed Abe R, Ogawa K, Maruyama Y, Nakamura N, Abe M. Spontaneous regression of diffuse large b-cell lymphoma harbouring epstein-barr virus a case report and review of the literature. J Clin Exp Hematop. 2007;47:23–6.CrossRefPubMed
16.
go back to reference Tanaka Y, Ishihara M, Miyoshi H, Hashimoto A, Shinzato I, Ohshima K. Spontaneous regression of diffuse large B-cell lymphoma in the small intestine with multiple lymphadenopathy. J Clin Exp Hematop. 2019;59:17–21.CrossRefPubMedPubMedCentral Tanaka Y, Ishihara M, Miyoshi H, Hashimoto A, Shinzato I, Ohshima K. Spontaneous regression of diffuse large B-cell lymphoma in the small intestine with multiple lymphadenopathy. J Clin Exp Hematop. 2019;59:17–21.CrossRefPubMedPubMedCentral
17.
go back to reference Krikorian JG, Portlock CS, Cooney P. Spontaneous regression of non-Hodgkin’s lymphoma a report of nine case. Cancer. 1980;46:2093–9.CrossRefPubMed Krikorian JG, Portlock CS, Cooney P. Spontaneous regression of non-Hodgkin’s lymphoma a report of nine case. Cancer. 1980;46:2093–9.CrossRefPubMed
18.
go back to reference Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin’s lymphomas. N Engl J Med. 1984;11:1471–5.CrossRef Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin’s lymphomas. N Engl J Med. 1984;11:1471–5.CrossRef
19.
go back to reference Puig N, Trudel S, Keats JJ, Li ZH, Braggio E, Ahmann GJ, et al. Spontaneous remission in a patient with t(4;14) translocation multiple myeloma. J Clin Oncol. 2009;27:e194–7.CrossRefPubMed Puig N, Trudel S, Keats JJ, Li ZH, Braggio E, Ahmann GJ, et al. Spontaneous remission in a patient with t(4;14) translocation multiple myeloma. J Clin Oncol. 2009;27:e194–7.CrossRefPubMed
21.
go back to reference Ichikawa A, Arakawa F, Kiyasu J, Sato K, Miyoshi H, Niino D, et al. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol. 2013;91:20–8.CrossRefPubMed Ichikawa A, Arakawa F, Kiyasu J, Sato K, Miyoshi H, Niino D, et al. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol. 2013;91:20–8.CrossRefPubMed
22.
go back to reference Gion Y, Iwaki N, Takata K, Takeuchi M, Nishida K, Orita Y, et al. Clinicopathological analysis of methotrexate-associated lymphoproliferative disorders: comparison of diffuse large B-cell lymphoma and classical Hodgkin lymphoma types. Cancer Sci. 2017;108:1271–80.CrossRefPubMedPubMedCentral Gion Y, Iwaki N, Takata K, Takeuchi M, Nishida K, Orita Y, et al. Clinicopathological analysis of methotrexate-associated lymphoproliferative disorders: comparison of diffuse large B-cell lymphoma and classical Hodgkin lymphoma types. Cancer Sci. 2017;108:1271–80.CrossRefPubMedPubMedCentral
23.
go back to reference Kurita D, Miyoshi H, Ichikawa A, Kato K, Imaizumi Y, Seki R, et al. Methotrexate-associated lymphoproliferative disorders in patients with rheumatoid arthritis clinicopathologic features and prognostic factors. Am J Surg Pathol. 2019;43:869–84.CrossRefPubMed Kurita D, Miyoshi H, Ichikawa A, Kato K, Imaizumi Y, Seki R, et al. Methotrexate-associated lymphoproliferative disorders in patients with rheumatoid arthritis clinicopathologic features and prognostic factors. Am J Surg Pathol. 2019;43:869–84.CrossRefPubMed
24.
go back to reference Kim SH, Kim TH, Sohn JW, Yoon HJ, Shin DH, Kim IS, et al. Primary pulmonary plasmacytoma presenting as multiple lung nodules. Korean J Intern Med. 2012;27:111–3.CrossRefPubMedPubMedCentral Kim SH, Kim TH, Sohn JW, Yoon HJ, Shin DH, Kim IS, et al. Primary pulmonary plasmacytoma presenting as multiple lung nodules. Korean J Intern Med. 2012;27:111–3.CrossRefPubMedPubMedCentral
25.
go back to reference Sekiguchi Y, Shimada A, Ichikawa K, Wakabayashi M, Sugimoto K, Ikeda K, et al. Epstein-Barr virus-positive multiple myeloma developing after immunosuppressant therapy for rheumatoid arthritis a case report and review of literature. Int J Clin Exp. 2015;8:2090–102. Sekiguchi Y, Shimada A, Ichikawa K, Wakabayashi M, Sugimoto K, Ikeda K, et al. Epstein-Barr virus-positive multiple myeloma developing after immunosuppressant therapy for rheumatoid arthritis a case report and review of literature. Int J Clin Exp. 2015;8:2090–102.
26.
go back to reference Tokunaga T, Hashimoto H, Yoshida Y, Sugimoto T, Mokuda S, Kosaka Y, et al. Immunoglobulin D-kappa multiple myeloma in a patient with rheumatoid arthritis: a case report and review of the literature. Mod Rheumatol Case Rep. 2021;5:22–8.CrossRefPubMed Tokunaga T, Hashimoto H, Yoshida Y, Sugimoto T, Mokuda S, Kosaka Y, et al. Immunoglobulin D-kappa multiple myeloma in a patient with rheumatoid arthritis: a case report and review of the literature. Mod Rheumatol Case Rep. 2021;5:22–8.CrossRefPubMed
27.
go back to reference Zhou T, Cheng J, Karrs J, Davies-Hill T, Pack SD, Xi L, et al. Clinicopathologic and molecular characterization of epstein-barr virus-positive plasmacytoma. Am J Surg Pathol. 2022;46:1364–79.CrossRefPubMed Zhou T, Cheng J, Karrs J, Davies-Hill T, Pack SD, Xi L, et al. Clinicopathologic and molecular characterization of epstein-barr virus-positive plasmacytoma. Am J Surg Pathol. 2022;46:1364–79.CrossRefPubMed
28.
go back to reference Ohgaki F, Takemoto Y, Paku S, Tatezuki J, Kumagai J, Shuto T, et al. Primary central nervous system other iatrogenic immunodeficiency-associated lymphoproliferative disorders presenting as extraosseous plasmacytoma with a progressive clinical course: a case report and literature review. Neuropathology. 2023;43:151–7.CrossRefPubMed Ohgaki F, Takemoto Y, Paku S, Tatezuki J, Kumagai J, Shuto T, et al. Primary central nervous system other iatrogenic immunodeficiency-associated lymphoproliferative disorders presenting as extraosseous plasmacytoma with a progressive clinical course: a case report and literature review. Neuropathology. 2023;43:151–7.CrossRefPubMed
29.
go back to reference Saito S, Kaneko Y, Yamaoka K, Tokuhira M, Takeuchi T. Distinct patterns of lymphocyte count transition in lymphoproliferative disorder in patients with rheumatoid arthritis treated with methotrexate. Rheumatology. 2017;56:940–6.CrossRefPubMed Saito S, Kaneko Y, Yamaoka K, Tokuhira M, Takeuchi T. Distinct patterns of lymphocyte count transition in lymphoproliferative disorder in patients with rheumatoid arthritis treated with methotrexate. Rheumatology. 2017;56:940–6.CrossRefPubMed
30.
go back to reference Berti A, Felicetti M, Peccatori S, Bortolotti R, Guella A, Vivaldi P, et al. EBV-induced lymphoproliferative disorders in rheumatic patients A systematic review of the literature. Joint Bone Spine. 2018;85:35–40.CrossRefPubMed Berti A, Felicetti M, Peccatori S, Bortolotti R, Guella A, Vivaldi P, et al. EBV-induced lymphoproliferative disorders in rheumatic patients A systematic review of the literature. Joint Bone Spine. 2018;85:35–40.CrossRefPubMed
31.
go back to reference Tokuhira M, Tanaka Y, Takahashi Y, Kimura Y, Tomikawa T, Anan T, et al. The clinical impact of absolute lymphocyte count in peripheral blood among patients with methotrexate - associated lymphoproliferative disorders. J Clin Exp Hematop. 2020;60:41–50.CrossRefPubMedPubMedCentral Tokuhira M, Tanaka Y, Takahashi Y, Kimura Y, Tomikawa T, Anan T, et al. The clinical impact of absolute lymphocyte count in peripheral blood among patients with methotrexate - associated lymphoproliferative disorders. J Clin Exp Hematop. 2020;60:41–50.CrossRefPubMedPubMedCentral
32.
go back to reference Saito S, Suzuki K, Yoshimoto K, Kaneko Y, Yamaoka K, Shimizu T, et al. Restoration of decreased T Helper 1 and CD8+ T cell subsets is associated with regression of lymphoproliferative disorders developed during methotrexate treatment. Front Immunol. 2018;9:621.CrossRefPubMedPubMedCentral Saito S, Suzuki K, Yoshimoto K, Kaneko Y, Yamaoka K, Shimizu T, et al. Restoration of decreased T Helper 1 and CD8+ T cell subsets is associated with regression of lymphoproliferative disorders developed during methotrexate treatment. Front Immunol. 2018;9:621.CrossRefPubMedPubMedCentral
33.
go back to reference Hoeller S, Tzankov A, Pileri SA, Went P, Dirnhofer S. Epstein-Barr virus-positive diffuse large B-cell lymphoma in elderly patients is rare in Western populations. Hum Pathol. 2010;41:352–7.CrossRefPubMed Hoeller S, Tzankov A, Pileri SA, Went P, Dirnhofer S. Epstein-Barr virus-positive diffuse large B-cell lymphoma in elderly patients is rare in Western populations. Hum Pathol. 2010;41:352–7.CrossRefPubMed
34.
go back to reference Hong JY, Yoon DH, Suh C, Huh J, Do IG, Sohn I, et al. EBV-positive diffuse large B-cell lymphoma in young adults: is this a distinct disease entity? Ann Oncol. 2015;26:548–55.CrossRefPubMed Hong JY, Yoon DH, Suh C, Huh J, Do IG, Sohn I, et al. EBV-positive diffuse large B-cell lymphoma in young adults: is this a distinct disease entity? Ann Oncol. 2015;26:548–55.CrossRefPubMed
35.
36.
go back to reference Tokuhira M, Kimura Y, Takahashi Y, Tomikawa T, Sagawa M, Anan T, et al. Impact Of Epstein-Barr viral infection in the regression of methotrexate-induced lymphoproliferative diseases in patients with rheumatoid arthritis. Blood. 2013;122:3006.CrossRef Tokuhira M, Kimura Y, Takahashi Y, Tomikawa T, Sagawa M, Anan T, et al. Impact Of Epstein-Barr viral infection in the regression of methotrexate-induced lymphoproliferative diseases in patients with rheumatoid arthritis. Blood. 2013;122:3006.CrossRef
37.
go back to reference Rosenblatt J, Avigan D. Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality? Blood. 2017;129:275–9.CrossRefPubMed Rosenblatt J, Avigan D. Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality? Blood. 2017;129:275–9.CrossRefPubMed
38.
go back to reference Ishibashi M, Tamura H, Sunakawa M, Kondo-Onodera A, Okuyama N, Hamada Y, et al. Myeloma drug resistance induced by binding of myeloma B7–H1 (PD-L1) to PD-1. Cancer Immunol Res. 2016;4:779–88.CrossRefPubMed Ishibashi M, Tamura H, Sunakawa M, Kondo-Onodera A, Okuyama N, Hamada Y, et al. Myeloma drug resistance induced by binding of myeloma B7–H1 (PD-L1) to PD-1. Cancer Immunol Res. 2016;4:779–88.CrossRefPubMed
39.
go back to reference Lee BH, Park Y, Kim JH, Kang KW, Lee SJ, Kim SJ, et al. PD-L1 expression in bone marrow plasma cells as a biomarker to predict multiple myeloma prognosis: developing a nomogram-based prognostic model. Sci Rep. 2020;10:12641.CrossRefPubMedPubMedCentral Lee BH, Park Y, Kim JH, Kang KW, Lee SJ, Kim SJ, et al. PD-L1 expression in bone marrow plasma cells as a biomarker to predict multiple myeloma prognosis: developing a nomogram-based prognostic model. Sci Rep. 2020;10:12641.CrossRefPubMedPubMedCentral
Metadata
Title
Spontaneous regression of multiple solitary plasmacytoma harboring Epstein–Barr virus: a case report and literature review
Authors
Wataru Kitamura
Hiroki Kobayashi
Minori Noda
Akiko Iseki
Yumi Sato
Yoshinobu Maeda
Shoichi Kuyama
Publication date
15-04-2024
Publisher
Springer Nature Singapore
Published in
International Journal of Hematology
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-024-03765-5
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine